Core Insights - The CEO of Progyny, Peter Anevski, purchased 79,500 shares on November 13, 2025, signaling potential confidence in the company's future performance [1][5][8] Transaction Summary - The transaction involved 79,500 shares with a total value of approximately $1.9 million, based on a weighted average purchase price of $24.29 per share [2] - Post-transaction, Anevski holds 680,251 shares, valued at around $16.6 million, representing 0.79% of Progyny's outstanding shares [2][5] Company Overview - Progyny reported a trailing twelve months (TTM) revenue of $1,268.69 million and a net income of $56.57 million [4] - The company's stock price was $24.95 as of December 2, 2025, reflecting a 60% increase over the past year [4] Market Context - The recent share purchase is one of the largest by Anevski since January 2023, significantly exceeding the median sell transaction of 20,086 shares [5] - The shares were acquired at $24.29, while the market price was $26.82 as of November 17, 2025, indicating a ~10.4% increase from the purchase price [5] Company Snapshot - Progyny specializes in fertility and family-building benefits, targeting large employers in the U.S. [6][7] - The company operates within the healthcare information services sector, leveraging a curated provider network to deliver value-added services [7] Strategic Insights - Anevski's purchase was made to offset tax withholding obligations, suggesting a belief in the stock's value at current prices [8] - The company has shown strong operational performance, with a reported 9% sales growth and near-100% customer retention [9] - Progyny is viewed as a favorable investment opportunity, trading at 12 times free cash flow and 14 times forward earnings, indicating it may be undervalued [10]

Group 1: Institutional Holdings - GAMMA Investing LLC increased its stake in Progyny by 233.9% in Q1, now owning 5,379 shares valued at $120,000 after purchasing an additional 3,768 shares [1] - Wealth Enhancement Advisory Services LLC acquired a new position worth $354,000 in Progyny during Q1 [1] - New York State Teachers Retirement System raised its stake by 0.7%, now holding 73,200 shares valued at $1,635,000 after buying 500 additional shares [1] - Principal Financial Group Inc. increased its position by 2.9%, owning 471,826 shares worth $10,541,000 after purchasing 13,246 shares [1] - Cerity Partners LLC grew its holdings by 116.9%, now owning 28,881 shares valued at $645,000 after buying 15,563 shares [1] - Hedge funds and institutional investors collectively own 94.93% of Progyny's stock [1] Group 2: Insider Transactions - Director Kevin K. Gordon sold 2,500 shares at an average price of $22.04, totaling $55,100, resulting in a 16.67% decrease in his position [2] - EVP Allison Swartz sold 2,398 shares at an average price of $22.96, totaling $55,058, leading to a 2.92% decrease in her ownership [2] - Insiders sold a total of 7,895 shares worth $179,311 over the last quarter, with insiders owning 9.40% of the company's stock [2] Group 3: Financial Performance - Progyny reported $0.19 earnings per share for the quarter, missing analysts' estimates of $0.42 by $0.23 [4] - The company had revenue of $332.87 million for the quarter, exceeding analyst estimates of $315.70 million, representing a 9.5% year-over-year increase [4] - Progyny's return on equity was 10.69% with a net margin of 4.28% [4] - The company has set Q3 2025 guidance at EPS and FY 2025 guidance at 1.700-1.780 EPS [4] Group 4: Stock Performance and Analyst Ratings - PGNY stock opened at $18.71, with a market cap of $1.61 billion, a P/E ratio of 31.71, and a P/E/G ratio of 1.59 [3] - The stock has a 12-month low of $13.39 and a high of $26.76, with 50-day and 200-day simple moving averages at $21.30 and $21.93, respectively [3] - Canaccord Genuity raised its target price from $21.00 to $23.00, maintaining a "hold" rating [5] - Truist Financial increased its price target from $24.00 to $27.00, also giving a "hold" rating [5] - Wall Street Zen upgraded Progyny from "hold" to "buy" [5] - The consensus rating for Progyny is "Moderate Buy" with a target price of $25.44 [5]